Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64,521,093
-
Total 13F shares
-
50,562,361
-
Share change
-
+3,842,685
-
Total reported value
-
$202,249,948
-
Put/Call ratio
-
0%
-
Price per share
-
$4.00
-
Number of holders
-
86
-
Value change
-
+$62,663,407
-
Number of buys
-
45
-
Number of sells
-
75
Institutional Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q2 2025
As of 30 Jun 2025,
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,562,361 shares.
The largest 10 holders included
Beryl Capital Management LLC, Pivotal bioVenture Partners Investment Advisor LLC, GLAZER CAPITAL, LLC, Sofinnova Investments, Inc., ODDO BHF ASSET MANAGEMENT SAS, Trium Capital LLP, BlackRock, Inc., VANGUARD GROUP INC, NEA Management Company, LLC, and ALPINE ASSOCIATES MANAGEMENT INC..
This page lists
86
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.